Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC
Revisit the OncLive On Air Episodes From February 2024
OncLive’s April Roundup of Key FDA Decisions in Oncology
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer